How has the nature of chemotherapy
and prostate cancer
evolved? Janna Andrews
, MD, explains that historically, there were not many options for patients who became resistant to androgen deprivation therapy
beyond palliative care. However, upon completion of the TAX
trials in 2004, it was determined that Docetaxel
was an effective therapy for improving metastatic castrate-resistant prostate cancer
N Engl J Med. 2004 Oct 7;351(15):1502-12.
Bio for Janna Andrews, MD
Faculty and Financial Disclosures:
Dr. Andrews has no relevant financial disclosures.